» Articles » PMID: 11247927

Generation of Oxidative Stress Contributes to the Development of Pulmonary Hypertension Induced by Hypoxia

Overview
Date 2001 Mar 15
PMID 11247927
Citations 91
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic hypoxia causes pulmonary hypertension and right ventricular hypertrophy associated with pulmonary vascular remodeling. Because hypoxia might promote generation of oxidative stress in vivo, we hypothesized that oxidative stress may play a role in the hypoxia-induced cardiopulmonary changes and examined the effect of treatment with the antioxidant N-acetylcysteine (NAC) in rats. NAC reduced hypoxia-induced cardiopulmonary alterations at 3 wk of hypoxia. Lung phosphatidylcholine hydroperoxide (PCOOH) increased at days 1 and 7 of the hypoxic exposure, and NAC attenuated the increase in lung PCOOH. Lung xanthine oxidase (XO) activity was elevated from day 1 through day 21, especially during the initial 3 days of the hypoxic exposure. The XO inhibitor allopurinol significantly inhibited the hypoxia-induced increase in lung PCOOH and pulmonary hypertension, and allopurinol treatment only for the initial 3 days also reduced the hypoxia-induced right ventricular hypertrophy and pulmonary vascular thickening. These results suggest that oxidative stress produced by activated XO in the induction phase of hypoxic exposure contributes to the development of chronic hypoxic pulmonary hypertension.

Citing Articles

Mitochondria in hypoxic pulmonary hypertension, roles and the potential targets.

Geng Y, Hu Y, Zhang F, Tuo Y, Ge R, Bai Z Front Physiol. 2023; 14:1239643.

PMID: 37645564 PMC: 10461481. DOI: 10.3389/fphys.2023.1239643.


Oxidative Stress and Antioxidant Therapy in Pulmonary Hypertension.

Poyatos P, Gratacos M, Samuel K, Orriols R, Tura-Ceide O Antioxidants (Basel). 2023; 12(5).

PMID: 37237872 PMC: 10215203. DOI: 10.3390/antiox12051006.


Pharmacology and Emerging Therapies for Group 3 Pulmonary Hypertension Due to Chronic Lung Disease.

Gonzales J, Fraidenburg D Pharmaceuticals (Basel). 2023; 16(3).

PMID: 36986517 PMC: 10058846. DOI: 10.3390/ph16030418.


New Drugs and Therapies in Pulmonary Arterial Hypertension.

Shah A, Beckmann T, Vorla M, Kalra D Int J Mol Sci. 2023; 24(6).

PMID: 36982922 PMC: 10058689. DOI: 10.3390/ijms24065850.


Natural Products for the Treatment of Pulmonary Hypertension: Mechanism, Progress, and Future Opportunities.

Zeng Z, Wang X, Cui L, Wang H, Guo J, Chen Y Curr Issues Mol Biol. 2023; 45(3):2351-2371.

PMID: 36975522 PMC: 10047369. DOI: 10.3390/cimb45030152.